Corcept Therapeutics Reports Q3 2026 Revenue Growth Driven by Lifyorli and Endocrinology Sales
Corcept Therapeutics (CORT) reported strong third-quarter 2026 financial results, with revenue reaching $340.5 million, a 64% increase year-over-year. This growth was primarily fueled by record sales in the endocrinology division and the rapid commercial scaling of Lifyorli, which generated $91.4 million in revenue following its April launch. The company's net income rose significantly to $126.8 million from $19.7 million in the prior year period, resulting in a diluted EPS of $1.01. Management reiterated full-year 2026 revenue guidance of $1.1 billion to $1.2 billion, supported by strong physician adoption and a robust clinical pipeline including relacorilant. Looking ahead, Corcept is targeting significant long-term growth, with an annual Cushing's syndrome revenue target of at least $2 billion by the end of the decade. The company also highlighted positive clinical data from its oncology and MASH programs as it prepares for key regulatory milestones in late 2026.
Tickers: $CORT
Topics: EPS Financial Guidance Net Income Pharmaceutical Sales Revenue Growth